Durvalumab: beside a new treatment under test

248 studies: a new drug, cell therapy or vaccine is what the study tests. Page 1 of 3. Open to participants first (57), then studies with results posted, then the rest; newest registration first within each.

• A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)Not yet recruitingNCT07908537Phase 3Report a problem
• A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung CancerNot yet recruitingNCT07796100Phase 3Report a problem
• NK Cells Plus ICI for SCLC MaintenanceRecruitingNCT07759856Phase 2Report a problem
• AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic CancerRecruitingNCT07619313Phase 1Report a problem
• A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)RecruitingNCT07554339Phase 3Report a problem
• Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)RecruitingNCT07531095Phase 1Report a problem
• Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular CarcinomaNot yet recruitingNCT07511504Phase 2Report a problem
• A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract CancerNot yet recruitingNCT07269158Phase 1/2Report a problem
• Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)Not yet recruitingNCT07247786Phase 2Report a problem
• Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular CancerNot yet recruitingNCT07226063Phase 2Report a problem
• Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular CarcinomaRecruitingNCT07175441Phase 2Report a problem
• A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung CancerRecruitingNCT07174583Phase 1/2Report a problem
• The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2Not yet recruitingNCT07146230Phase 2Report a problem
• Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract CancerRecruitingNCT07107750Phase 1Report a problem
• MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract CarcinomaRecruitingNCT07036380Phase 2Report a problem
• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerRecruitingNCT06890598Phase 3Report a problem
• A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)RecruitingNCT06780137Phase 1/2Report a problem
• Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyRecruitingNCT06769126Phase 2Report a problem
• Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract CancerRecruitingNCT06708858Phase 2Report a problem
• Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)RecruitingNCT06698250Phase 2Report a problem
• Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC RegimenRecruitingNCT06680050Phase 2Report a problem
• A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06667908Phase 2Report a problem
• Perioperative Therapies in Locally Advanced Unresectable Gastric CancerRecruitingNCT06630130Phase 2Report a problem
• Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)RecruitingNCT06564623Phase 1Report a problem
• Microbiota Modification for Immuno-oncology in Hepatocellular CarcinomaRecruitingNCT06551272Phase 2Report a problem
• A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)RecruitingNCT06551142Phase 1Report a problem
• CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract CancersRecruitingNCT06548412Phase 1/2Report a problem
• A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder CancerRecruitingNCT06503614Phase 2Report a problem
• Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerRecruitingNCT06463665Phase 2Report a problem
• Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung CancerRecruitingNCT06287775Phase 1/2Report a problem
• Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerRecruitingNCT06282575Phase 3Report a problem
• Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract CancerNot yet recruitingNCT06255262Phase 1/2Report a problem
• BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingNCT06111326Phase 1/2Report a problem
• Durvalumab and Oleclumab in Resectable PDACRecruitingNCT06060405Phase 2Report a problem
• MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung CancerRecruitingNCT05903092Phase 2Report a problem
• LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung CancerRecruitingNCT05886439Phase 1/2Report a problem
• Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint InhibitorsRecruitingNCT05834413Not applicableReport a problem
• IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)RecruitingNCT05742607Phase 2Report a problem
• Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCRecruitingNCT05733598Phase 2Report a problem
• Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLCNot yet recruitingNCT05668767Phase 2Report a problem
• REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)RecruitingNCT05632809Phase 2Report a problem
• Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)RecruitingNCT05620628Phase 2Report a problem
• Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-PaclitaxelRecruitingNCT05582538Phase 2Report a problem
• A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular CarcinomaRecruitingNCT05155189Phase 1Report a problem
• Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung CancerRecruitingNCT05136846Phase 1Report a problem
• Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingNCT05061550Phase 2Report a problem
• Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICIRecruitingNCT04954599Phase 1/2Report a problem
• Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian CancerRecruitingNCT04918186Phase 2Report a problem
• Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsRecruitingNCT04900818Phase 1Report a problem
• A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLCRecruitingNCT04550104Phase 1Report a problem
• Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung CancerRecruitingNCT04499053Phase 2Report a problem
• AZD6738 Plus Durvalumab in Biliary Tract CancerRecruitingNCT04298008Phase 2Report a problem
• DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancErRecruitingNCT04106115Phase 1/2Report a problem
• RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II TrialRecruitingNCT04105270Phase 2Report a problem
• Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver CancerRecruitingNCT03942328Phase 1/2Report a problem
• Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor MalignanciesRecruitingNCT03772561Phase 1Report a problem
• Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerRecruitingNCT03606967Phase 2Report a problem
• A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid TumorsCompletedNCT05712356Phase 2Results postedReport a problem
• A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 InhibitionActive, not recruitingNCT05061134Phase 2Results postedReport a problem
• Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver TransplantTerminatedNCT05027425Phase 2Results postedReport a problem
• Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid TumoursActive, not recruitingNCT04999969Phase 2Results postedReport a problem
• Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted AntibodiesTerminatedNCT04902040Phase 1/2Results postedReport a problem
• Study of AZD2811 + Durvalumab in ES-SCLCActive, not recruitingNCT04745689Phase 2Results postedReport a problem
• A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.CompletedNCT04495179Phase 2Results postedReport a problem
• Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic CholangiocarcinomaCompletedNCT04301778Phase 2Results postedReport a problem
• CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast CancerActive, not recruitingNCT04176848Phase 2Results postedReport a problem
• An Open-label, Phase II Study of AZD4635 in Patients With Prostate CancerCompletedNCT04089553Phase 2Results postedReport a problem
• COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRCActive, not recruitingNCT04068610Phase 1/2Results postedReport a problem
• AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT04019288Phase 1/2Results postedReport a problem
• Durvalumab and Tremelimumab for Pediatric MalignanciesActive, not recruitingNCT03837899Phase 1/2Results postedReport a problem
• Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 TrialCompletedNCT03801902Phase 1Results postedReport a problem
• Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY TrialTerminatedNCT03753919Phase 2Results postedReport a problem
• A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerActive, not recruitingNCT03742102Phase 1/2Results postedReport a problem
• Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation ApproachCompletedNCT03702179Phase 2Results postedReport a problem
• Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular LymphomaTerminatedNCT03685344Phase 1Results postedReport a problem
• CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and TremelimumabCompletedNCT03638141Phase 2Results postedReport a problem
• MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.CompletedNCT03611556Phase 1/2Results postedReport a problem
• Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung CancerCompletedNCT03581487Phase 1/2Results postedReport a problem
• Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT03522584Phase 1/2Results postedReport a problem
• DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated CancersTerminatedNCT03439085Phase 2Results postedReport a problem
• Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary TractCompletedNCT03430895Phase 2Results postedReport a problem
• Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic AdenocarcinomaTerminatedNCT03376659Phase 1/2Results postedReport a problem
• Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung CancerCompletedNCT03373760Phase 2Results postedReport a problem
• Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive, not recruitingNCT03334617Phase 2Results postedReport a problem
• Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced MalignanciesTerminatedNCT03323398Phase 1/2Results postedReport a problem
• A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell MalignanciesCompletedNCT03310619Phase 1/2Results postedReport a problem
• Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)CompletedNCT03258593Phase 1Results postedReport a problem
• A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal CancerCompletedNCT03206073Phase 1/2Results postedReport a problem
• Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT03204812Phase 2Results postedReport a problem
• Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLCCompletedNCT03164772Phase 1/2Results postedReport a problem
• Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck CancerCompletedNCT03162224Phase 1/2Results postedReport a problem
• Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast CancerCompletedNCT03132467Early Phase 1Results postedReport a problem
• Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT03026062Phase 2Results postedReport a problem
• Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer PatientsCompletedNCT03019003Phase 1Results postedReport a problem
• Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on ChemotherapyCompletedNCT03007407Phase 2Results postedReport a problem
• A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal MalignanciesCompletedNCT02963831Phase 1/2Results postedReport a problem
• Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 MutationCompletedNCT02953457Phase 2Results postedReport a problem
• Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung CancerCompletedNCT02898116Phase 1/2Results postedReport a problem
• Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLCTerminatedNCT02805660Phase 1/2Results postedReport a problem
• TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian CancerCompletedNCT02764333Phase 2Results postedReport a problem

← Durvalumab